#1 Clinical Trials Search in Europe

Ucart20X22

UCART20X22 is an innovative cell therapy being studied in clinical trials for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL). This article explores the ongoing research, potential benefits, and important information about this new treatment approach for patients who have not responded to previous therapies.

Table of Contents

What is UCART20x22?

UCART20x22 is an innovative medical treatment currently being studied for patients with certain types of blood cancers. It is classified as a cell therapy, which means it uses specially modified cells to fight disease. More specifically, UCART20x22 is a type of CAR T-cell therapy, where T-cells (a type of immune cell) are engineered to target and attack cancer cells.[1]

What condition does UCART20x22 treat?

UCART20x22 is being developed to treat relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL). This is a type of blood cancer that affects B-cells, which are part of the immune system. “Relapsed” means the cancer has returned after treatment, while “refractory” means the cancer has not responded to treatment.[1]

How does UCART20x22 work?

UCART20x22 works by targeting two specific proteins found on the surface of B-cells: CD20 and CD22. The therapy uses T-cells that have been genetically modified to recognize and attack cells displaying these proteins. This dual-targeting approach may make the treatment more effective against cancer cells.[1]

Current Clinical Trial

UCART20x22 is currently being studied in a clinical trial called NatHaLi-01. This is a Phase 1/2a study, which means it’s an early-stage trial designed to test the safety and initial effectiveness of the treatment. The trial has two main parts:[1]

  1. Dose-Finding Part: This part aims to determine the safest and most effective dose of UCART20x22.
  2. Dose-Expansion Part: This part will further test the chosen dose in more patients to confirm its safety and effectiveness.

Who is eligible for the UCART20x22 trial?

The trial is open to patients who meet certain criteria, including:[1]

  • Adults aged 18 to 80 years
  • Diagnosed with relapsed or refractory B-cell Non-Hodgkin Lymphoma
  • Cancer that is positive for CD20 and/or CD22 proteins
  • Have received at least two prior lines of treatment
  • Have adequate organ function
  • Have at least one measurable tumor

Who is not eligible for the UCART20x22 trial?

Some factors that may exclude a patient from participating include:[1]

  • Recent stem cell transplant or certain other therapies
  • Active infections, including COVID-19
  • Certain heart conditions
  • Active central nervous system lymphoma
  • Pregnancy or breastfeeding

What are the objectives of the UCART20x22 trial?

The main goals of the trial are:[1]

  • To assess the safety and tolerability of UCART20x22
  • To determine the most appropriate dose for future studies
  • To evaluate how well the treatment works against the cancer (its “antitumor activity”)
  • To study how long the treatment remains effective

How is safety monitored in the trial?

The trial closely monitors patients for any side effects or adverse events. This includes:[1]

  • Tracking the nature and severity of any side effects
  • Monitoring for serious adverse events
  • Assessing the effects of the lymphodepletion regimen (a preparatory treatment given before UCART20x22)
  • Evaluating how patients’ immune systems recover after treatment
Aspect Details
Treatment Name UCART20X22
Type of Therapy Universal Engineered Chimeric Antigen Receptor T-cells
Target Condition Relapsed or refractory B-cell Non-Hodgkin Lymphoma
Administration Method Intravenous injection
Age Range for Trial 18 to 80 years
Prior Treatments Required At least 2 lines of prior treatment
Main Trial Objectives Assess safety, determine appropriate dose, evaluate effectiveness
Key Eligibility Criteria R/R mature B-NHL, adequate organ function, ECOG status 0 or 1
Key Exclusion Criteria Active infections, recent allogeneic stem cell transplant, active CNS lymphoma

FAQ

  • What is UCART20X22? UCART20X22 is a type of cell therapy called Universal Engineered Chimeric Antigen Receptor T-cells. It targets two proteins, CD20 and CD22, found on the surface of B-cells in Non-Hodgkin Lymphoma.
  • Who might benefit from UCART20X22 treatment? This treatment is being studied for patients aged 18 to 80 with relapsed or refractory B-cell Non-Hodgkin Lymphoma who have not responded to at least two prior lines of treatment.
  • How is UCART20X22 administered? UCART20X22 is given as an intravenous (IV) injection. Before receiving the treatment, patients undergo a process called lymphodepletion to prepare their body for the therapy.
  • What are the main goals of the clinical trial? The main objectives are to assess the safety and tolerability of UCART20X22, determine the appropriate dose, and evaluate its effectiveness in treating B-cell Non-Hodgkin Lymphoma.
  • Are there any specific health conditions that might prevent someone from participating in the trial? Yes, patients with active infections, uncontrolled cardiovascular disease, or a history of certain other cancers may not be eligible. Additionally, those who have recently received other cancer treatments or have active central nervous system lymphoma may be excluded.

Ongoing Clinical Trials on Ucart20X22

  • Study on UCART20x22 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Using a Drug Combination

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

Glossary

  • B-cell Non-Hodgkin Lymphoma (B-NHL): A type of cancer that affects B-cells, a part of the immune system. It occurs when these cells grow abnormally and can spread to other parts of the body.
  • Relapsed or Refractory (R/R): Relapsed means the cancer has returned after treatment. Refractory means the cancer has not responded to treatment or has stopped responding.
  • Chimeric Antigen Receptor (CAR) T-cells: Immune cells that have been genetically modified to target and attack specific cancer cells.
  • Lymphodepletion (LD): A process of reducing the number of existing immune cells in the body to prepare for cell therapy treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Dose-Finding: The process of determining the safest and most effective dose of a new treatment.
  • Dose-Expansion: A phase in clinical trials where more patients receive the treatment at the dose determined to be safe and potentially effective.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Events (SAEs): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-ucart20x22-for-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-using-a-drug-combination/